Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients

(MedPage Today) -- Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that omitted chemotherapy, a small prospective...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news